Xeris Biopharma Holdings, Inc. Share Price & Technical Analysis
XERS · $6.19 (-2.98%)
Healthcare / Drug Manufacturers - Specialty & Generic
$6.19
-2.98%
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related v…
Price chart
Seasonality
May has 3 positive and 1 negative years (last 5 years shown)
0% return in May, 20% avg return in past 3 year May month.
-38% return in 2026, 86% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -6% | -16% | -18% | 3% | 0% | – | – | – | – | – | – | – | -38% |
| 25 | 6% | 9% | 45% | -16% | 7% | -6% | 9% | 56% | 5% | 20% | -26% | 10% | 117% |
| 24 | 9% | 24% | -29% | -22% | 35% | -4% | 14% | 12% | 0% | 14% | 0% | 3% | 56% |
| 23 | -8% | 17% | 14% | 44% | 18% | 0% | 0% | -12% | -17% | 0% | 0% | 28% | 84% |
| 22 | -30% | 9% | 8% | -8% | -8% | -32% | -7% | 21% | -6% | 0% | -6% | -13% | -71% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Uptrend
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.08B
P/E ratio
89.29
52W high
$10.08
52W low
$4.30
Volume
10,54,441
Beta
0.92
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Xeris Biopharma Holdings, Inc. share price today?
- Xeris Biopharma Holdings, Inc. (XERS) last traded around $6.19 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does XERS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for XERS. Download the app for real-time alerts.
- How can I analyze Xeris Biopharma Holdings, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.